| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | OX |
| Uniprot No | P41217 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-278aa |
| 氨基酸序列 | MERLVIRMPFSHLSTYSLVWVMAAVVLCTAQVQVVTQDEREQLYTPASLKCSLQNAQEALIVTWQKKKAVSPENMVTFSENHGVVIQPAYKDKINITQLGLQNSTITFWNITLEDEGCYMCLFNTFGFGKISGTACLTVYVQPIVSLHYKFSEDHLNITCSATARPAPMVFWKVPRSGIENSTVTLSHPNGTTSVTSILHIKDPKNQVGKEVICQVLHLGTVTDFKQTVNKGYWFSVPLLLSIVSLVILLVLISILLYWKRHRNQDRGELSQGVQKMT |
| 预测分子量 | 31,2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于OX重组蛋白的3篇参考文献示例(内容为虚构，仅作参考)：
1. **《Recombinant OX Protein Enhances T-cell Activation in Cancer Immunotherapy》**
- 作者：Smith A, et al.
- 摘要：研究通过重组OX蛋白体外刺激T细胞，证明其能显著增强T细胞增殖及抗肿瘤活性，为OX蛋白在免疫治疗中的应用提供实验依据。
2. **《Structural Characterization of OX Recombinant Protein and Its Ligand Binding Mechanism》**
- 作者：Zhang Y, et al.
- 摘要：利用X射线晶体学解析OX重组蛋白的三维结构，揭示其与配体结合的关键位点，为靶向药物设计奠定基础。
3. **《OX Recombinant Protein Attenuates Inflammatory Response in Autoimmune Disease Models》**
- 作者：Lee H, et al.
- 摘要：在小鼠类风湿性关节炎模型中，重组OX蛋白通过调控NF-κB通路抑制炎症因子释放，展现潜在治疗价值。
(注：以上文献为示例，实际引用需检索PubMed、Web of Science等数据库获取真实文献。)
**Background of OX Recombinant Proteins**
OX recombinant proteins are engineered molecules derived from the OX family of proteins, primarily associated with immune regulation and cellular signaling. The term "OX" often refers to proteins like OX40 (CD134), a member of the tumor necrosis factor receptor superfamily (TNFRSF), and its ligand OX40L (CD252), which play pivotal roles in modulating T-cell activation, survival, and immune response amplification. These proteins are critical in adaptive immunity, particularly in enhancing effector T-cell function and inhibiting regulatory T-cell activity, making them attractive targets for immunotherapy.
The development of recombinant OX proteins leverages genetic engineering techniques to produce purified, functional versions of these molecules in heterologous systems (e.g., mammalian, insect, or bacterial cells). Recombinant OX40 or OX40L typically retains the native structure, enabling interaction with their cognate receptors or ligands. This approach ensures high specificity and consistency, essential for research and therapeutic applications.
In biomedical research, OX recombinant proteins are widely used to study immune checkpoint pathways, investigate mechanisms of autoimmune diseases, and explore cancer immunotherapy strategies. For instance, agonist antibodies or recombinant OX40L are tested to stimulate anti-tumor T-cell responses, while antagonists may mitigate excessive inflammation in autoimmune conditions.
Therapeutic development focuses on harnessing OX pathways to either enhance immune attack against tumors or suppress aberrant immune activity. Clinical trials have evaluated OX40-targeting agents in cancers like melanoma and lymphoma, highlighting their potential to improve checkpoint inhibitor therapies.
Overall, OX recombinant proteins serve as vital tools for dissecting immune biology and advancing immunotherapies, bridging molecular insights with clinical innovation. Their versatility underscores their significance in both basic science and translational medicine.
×
